Biocon Limited
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, a… Read more
Biocon Limited (BIOCON) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.024x
Based on the latest financial reports, Biocon Limited (BIOCON) has a cash flow conversion efficiency ratio of 0.024x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹8.03 Billion) by net assets (₹330.55 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Biocon Limited - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Biocon Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Biocon Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biocon Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Metaplanet Inc.
PINK:MTPLF
|
N/A |
|
Mankind Pharma Ltd
NSE:MANKIND
|
0.014x |
|
Sichuan Biokin Pharmaceutical Co. Ltd. A
SHG:688506
|
N/A |
|
Dr. Ing. h.c. F. Porsche AG
PINK:DRPRF
|
0.047x |
|
Fortress Transportation and Preferred Series B
NASDAQ:FTAIO
|
-0.514x |
|
Scorpio Tankers Inc
NYSE:STNG
|
0.044x |
|
ACADIA Pharmaceuticals Inc
NASDAQ:ACAD
|
-0.040x |
|
ASR Microelectronics Co. Ltd. A
SHG:688220
|
N/A |
Annual Cash Flow Conversion Efficiency for Biocon Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Biocon Limited from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹277.12 Billion | ₹40.61 Billion | 0.147x | +25.39% |
| 2024-03-31 | ₹252.75 Billion | ₹29.54 Billion | 0.117x | +41.88% |
| 2023-03-31 | ₹224.89 Billion | ₹18.52 Billion | 0.082x | -33.70% |
| 2022-03-31 | ₹94.70 Billion | ₹11.77 Billion | 0.124x | -8.85% |
| 2021-03-31 | ₹85.08 Billion | ₹11.60 Billion | 0.136x | -21.56% |
| 2020-03-31 | ₹73.83 Billion | ₹12.83 Billion | 0.174x | +0.95% |
| 2019-03-31 | ₹67.07 Billion | ₹11.55 Billion | 0.172x | +46.87% |
| 2018-03-31 | ₹56.48 Billion | ₹6.62 Billion | 0.117x | -4.51% |
| 2017-03-31 | ₹52.14 Billion | ₹6.40 Billion | 0.123x | +1.83% |
| 2016-03-31 | ₹43.67 Billion | ₹5.26 Billion | 0.121x | +96.97% |
| 2015-03-31 | ₹34.43 Billion | ₹2.11 Billion | 0.061x | -66.07% |
| 2014-03-31 | ₹31.09 Billion | ₹5.61 Billion | 0.180x | +5.63% |
| 2013-03-31 | ₹27.60 Billion | ₹4.71 Billion | 0.171x | -31.11% |
| 2012-03-31 | ₹22.76 Billion | ₹5.64 Billion | 0.248x | -36.57% |
| 2011-03-31 | ₹20.71 Billion | ₹8.09 Billion | 0.391x | +58.86% |
| 2010-03-31 | ₹17.92 Billion | ₹4.41 Billion | 0.246x | +297.12% |
| 2009-03-31 | ₹15.36 Billion | ₹950.95 Million | 0.062x | -71.22% |
| 2008-03-31 | ₹14.77 Billion | ₹3.18 Billion | 0.215x | +51.28% |
| 2007-03-31 | ₹10.68 Billion | ₹1.52 Billion | 0.142x | +56.54% |
| 2006-03-31 | ₹8.91 Billion | ₹809.89 Million | 0.091x | -60.93% |
| 2005-03-31 | ₹7.41 Billion | ₹1.72 Billion | 0.233x | +1.77% |
| 2004-03-31 | ₹5.63 Billion | ₹1.29 Billion | 0.229x | -- |